Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes

Nauck, Michael, Frid, Anders, Hermansen, Kjeld, Shah, Nalini S., Tankova, Tsvetalina, Mitha, Ismail H., Zdravkovic, Milan, Düring, Maria +2 more·2009·Diabetes Care
DOI 10.2337/dc08-1355

Cited by (999)

Items 501–600 of 999

  1. Pharmacologic Treatment of Type 2 Diabetes
    Linda Tran, Angela Zielinski, Arpi H. Roach, Jennifer A. Jende, Ann Marie Householder, Emily E. Cole, Shuruq A. Atway, Melinda Amornyard, Mallory L. Accursi, Suzanna W. Shieh et al. · 2015 · Annals of Pharmacotherapy
  2. Glucose Lowering Treatment Modalities of Type 2 Diabetes Mellitus
    Asena Gökçay Canpolat, Mustafa Şahi̇n · 2020 · Advances in experimental medicine and biology
  3. Willingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results
    JOHAN H. JENDLE, Ole Torffvit, Martin Ridderstråle, Åsa Ericsson, B. Nilsen, Mette Bøgelund · 2012 · Journal of Medical Economics
  4. Metformin-Associated Gastrointestinal Adverse Events Are Reduced by Probiotics: A Meta-Analysis
    Izabela Szymczak-Pajor, Józef Drzewoski, Sylwia Wenclewska, Agnieszka Śliwińska · 2024 · Pharmaceuticals
  5. Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: Promises and challenges
    Zhidong Zhou, Ling Yi, Karolina Popławska-Domaszewicz, К. Ray Chaudhuri, Joseph J. Jankovic, Eng King Tan · 2025 · Pharmacological Research
  6. From Theory to Clinical Practice in the Use of GLP-1 Receptor Agonists and DPP-4 Inhibitors Therapy
    Ilaria Dicembrini, Laura Pala, Carlo Maria Rotella · 2011 · Experimental Diabetes Research
  7. The Place of GLP-1–Based Therapy in Diabetes Management: Differences Between DPP-4 Inhibitors and GLP-1 Receptor Agonists
    Dara L. Eckerle Mize, Marzieh Salehi · 2013 · Current Diabetes Reports
  8. Is it Time to Expand Glucagon-like Peptide-1 Receptor Agonist Use for Weight Loss in Patients Without Diabetes?
    Wendy H. Updike, Olivia Pane, Rachel B. Franks, Faizah Saber, Farah Abdeen, Derek D. Balazy, Nicholas W. Carris · 2021 · Drugs
  9. Patient preferences for anti-hyperglycaemic medication for type 2 diabetes mellitus in China: findings from a national survey
    Shimeng Liu, Jing Liu, Lei Si, Xiong Ke, Liu Liu, Yanfeng Ren, Shiyi Bao, Fuming Li, Yijiang Yu, Qi Pan et al. · 2023 · BMJ Global Health
  10. Effects of GLP-1 Agonists on mortality and arrhythmias in patients with Type II diabetes
    Mohammed Al‐Sadawi, Faisal M. Aslam, Michael Tao, Mahmoud Alsaiqali, Ibrahim O. Almasry, Roger Fan, Eric J. Rashba, Abhijeet Singh · 2023 · IJC Heart & Vasculature
  11. Pharmacological Actions of Glucagon-Like Peptide-1, Gastric Inhibitory Polypeptide, and Glucagon
    Revathi Sekar, Kailash Singh, Aloysius Wilfred Raj Arokiaraj, Bkc Chow · 2016 · International review of cytology
  12. Effects of Liraglutide on β-Cell-Specific Glucokinase-Deficient Neonatal Mice
    Jun Shirakawa, Ritsuko Tanami, Yu Togashi, Kazuki Tajima, Kazuki Orime, Naoto Kubota, Takashi Kadowaki, Yoshio Goshima, Yasuo Terauchi · 2012 · Endocrinology
  13. Incretin-based therapy: how do incretin mimetics and DPP-4 inhibitors fit into treatment algorithms for type 2 diabetic patients?
    Michael Albrecht Nauck, Ulf Smith · 2009 · Best Practice & Research Clinical Endocrinology & Metabolism
  14. Prediction of response to GLP-1 receptor agonist therapy in Japanese patients with type 2 diabetes
    Kenjiro Imai, Tetsuro Tsujimoto, Atsushi Goto, Maki Goto, Miyako Kishimoto, Ritsuko Yamamoto‐Honda, Hiroshi Noto, Hiroshi Kajio, Mitsuhiko Noda · 2014 · Diabetology & Metabolic Syndrome
  15. Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Venous Thromboembolism: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
    Yiwen Liu, Liyun He, Shumeng Han, Fan Ping, Wei Li, Lingling Xu, Huabing Zhang, Yuxiu Li · 2025 · Journal of the American Heart Association
  16. Clinical Effects of Liraglutide in a Real-World Setting in Spain: eDiabetes-Monitor SEEN Diabetes Mellitus Working Group Study
    Pedro Mezquita‐Raya, Rebeca Reyes‐García, Óscar Moreno, Javier Escalada, Miguel Ángel Rubio, Martin Lopez de la Torre Casares · 2015 · Diabetes Therapy
  17. ROOTS: A multicenter study in Belgium to evaluate the effectiveness and safety of liraglutide (Victoza®) in type 2 diabetic patients
    Martin Buysschaert, Dirk D’Hooge, Vanessa Preumont · 2015 · Diabetes & Metabolic Syndrome Clinical Research & Reviews
  18. Glucagon-Like Peptide-1 Receptor Agonist Use and Renal Impairment: A Retrospective Analysis of an Electronic Health Records Database in the U.S. Population
    Kristina Secnik Boye, Fady T. Botros, Axel Haupt, Brad Woodward, Maureen J. Lage · 2018 · Diabetes Therapy
  19. Pediatric Type 2 Diabetes: Not a Mini Version of Adult Type 2 Diabetes
    Talia A. Hitt, Lorraine E. Levitt Katz · 2020 · Endocrinology and Metabolism Clinics of North America
  20. Hypoglycemia is associated with a higher risk of mortality and arrhythmias in ST-elevation myocardial infarction, irrespective of diabetes
    Basel Humos, Ziyad Riyad Mahfoud, Soha Roger Dargham, Jassim M. S. Al Suwaidi, Hani M. Jneid, Charbel Abi Khalil · 2022 · Frontiers in Cardiovascular Medicine
  21. Investigation of an active film coating to prepare new fixed-dose combination tablets for treatment of diabetes
    Ju‐Young Kim, Dong‐Wook Kim, Yun-Mo Kuk, Chun‐Woong Park, Yun-Seok Rhee, Tack-Oon Oh, Kwon-Yeon Weon, Eun‐Seok Park · 2012 · International Journal of Pharmaceutics
  22. Real-World Cost-Effectiveness: Lower Cost of Treating Patients to Glycemic Goal with Liraglutide versus Exenatide
    Mitch DeKoven, Won Chan Lee, Jonathan R. Bouchard, Marjan Massoudi, J Langer · 2014 · Advances in Therapy
  23. Glucagon-like peptide-1 analogues for type 2 diabetes
    John P.H. Wilding, Kevin J Hardy · 2011 · BMJ
  24. Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus
    Michael E. Cobble · 2012 · Diabetology & Metabolic Syndrome
  25. Enhancing pediatric clinical trial feasibility through the use of Bayesian statistics
    Robin A. Huff, Jeffrey D. Maca, Mala Puri, Earl W Seltzer · 2017 · Pediatric Research
  26. Incretin-based therapies: new treatments for type 2 diabetes in the new millennium
    Michael Horowitz · 2009 · Therapeutics and Clinical Risk Management
  27. Add-On Treatment with Liraglutide Improves Glycemic Control in Patients with Type 2 Diabetes on Metformin Therapy
    Chiefari, Eusebio, Capula, Carmelo, Vero, Ada, Oliverio, Rosa, Puccio, Luigi, Liguori, Rossella, Pullano, Vittorio, Greco, Manfredi, Foti, Daniela, Tirinato, Domenico et al. · 2015 · Diabetes Technology & Therapeutics
  28. Liraglutide therapy beyond glycemic control: An observational study in Indian patients with type 2 diabetes in real world setting
    Jothydev Kesavadev, Arun Shankar, Gopika Krishnan, Sunitha Jothydev · 2012 · International Journal of General Medicine
  29. A review of newer treatment approaches for type-2 diabetes: Focusing safety and efficacy of incretin based therapy
    Regin Elsa George, Siby Joseph · 2013 · Saudi Pharmaceutical Journal
  30. New Perspectives in Type 2 Diabetes, Cardiovascular Risk, and Treatment Goals
    Carol Wysham · 2010 · Postgraduate Medicine
  31. Incretins: Clinical Perspectives, Relevance, and Applications for the Primary Care Physician in the Treatment of Patients With Type 2 Diabetes Mellitus
    Jeff Unger · 2010 · Mayo Clinic Proceedings
  32. Impact of glucagon‐like peptide‐1 on endothelial function
    Åke Sjöholm · 2009 · Diabetes Obesity and Metabolism
  33. GLP-1 receptor agonists today
    Michel Marre, Alfred Penfornis · 2011 · Diabetes Research and Clinical Practice
  34. Personalizing guidelines for diabetes management: twilight or dawn of the expert?
    Stavroula Α. Paschou, Richard David Leslie · 2013 · BMC Medicine
  35. Evaluation of the long-term cost-effectiveness of liraglutide therapy for patients with type 2 diabetes in France
    Ronan Roussel, Luc Martinez, Tom Vandebrouck, Habiba Douik, Patrick Emiel, Matthieu Guéry, Barnaby Hunt, William J. Valentine · 2015 · Journal of Medical Economics
  36. The role of GLP ‐1 receptor agonists as weight loss agents in patients with and without type 2 diabetes
    Shujah Dar, Abd A. Tahrani, Milan K. Piya · 2015 · Practical Diabetes
  37. Predictors of treatment response to liraglutide in type 2 diabetes in a real-world setting
    ReaL (NN2211-4118) Study Group*, Natalino Simioni, Cesare Berra, Massimo Boemi, Antonio Carlo Bossi, Riccardo Candido, Graziano Di Cianni, Simona Frontoni, Stefano Genovese, Paola Ponzani et al. · 2018 · Acta Diabetologica
  38. Incretin-Based Therapy and Type 2 Diabetes
    Kristine Juul Hare, Filip Krag Knop · 2010 · Vitamins and hormones
  39. Structured lifestyle modification as an adjunct to obesity pharmacotherapy: there is much to learn
    Enda E. Murphy, Francis Martin Finucane · 2024 · International Journal of Obesity
  40. Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity
    Dilek Yazıcı, Hale Yapıcı Eser, Sinem Kucuksarac Kiyici, Seda Sancak, Havva Sezer, Melin Uygur, Volkan Yumuk · 2022 · Obesity Facts
  41. Second line therapy: type 2 diabetic subjects failing on metformin GLP‐1/DPP‐IV inhibitors versus sulphonylurea/insulin: For GLP‐1/DPP‐IV inhibitors
    Ajay Kumar · 2012 · Diabetes/Metabolism Research and Reviews
  42. Emerging Therapeutic Approaches for the Management of Diabetes Mellitus and Macrovascular Complications
    Sherita Hill Golden · 2011 · The American Journal of Cardiology
  43. Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C <8.0%.
    A. King, E. Montanya, R. Pratley, L. Blonde, C. B. Svendsen, M. Donsmark, G. Sesti · 2013 · Endocrine Practice
  44. Recent development of single preparations and fixed-dose combination tablets for the treatment of non-insulin-dependent diabetes mellitus
    Jianwen Li, He Lian · 2016 · Archives of Pharmacal Research
  45. Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK
    Gabriela Vega-Hernandez, Radek Wojcik, Max Schlueter · 2017 · Diabetes Therapy
  46. Lixisenatide (Adlyxin): A Once-Daily Incretin Mimetic Injection for Type-2 Diabetes.
    Nicholas Leon, Richard J. LaCoursiere, Deirdre Yarosh, Roshni S. Patel · 2017 · PubMed Central
  47. Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes
    Stewart B. Harris, Martin J. Abrahamson, Antonio Ceriello, Guillaume Charpentier, Marc Evans, Roger Lehmann, Andreas Liebl, Sultan Linjawi, Richard I. G. Holt, Nóra Hosszúfalusi et al. · 2020 · Drugs
  48. Liraglutide for treating type 1 diabetes
    Thomas Fremming Dejgaard, Christian Seerup Frandsen, Jens Juul Holst, Sten Madsbad · 2016 · Expert Opinion on Biological Therapy
  49. Weight loss and side-effects of liraglutide and lixisenatide in obesity and type 2 diabetes mellitus
    Lee, Jeongmin, Kim, Raeun, Kim, Min-Hee, Lee, Seung-Hwan, Cho, Jae-Hyoung, Lee, Jung Min, Jang, Sang-Ah, Kim, Hun-Sung · 2023 · Primary care diabetes
  50. Evaluation of the effectiveness of liraglutide and sitagliptin in type 2 diabetes: a retrospective study in <scp>UK</scp> primary care
    Nyeland, M. E., Ploug, U. J., Richards, A., Garcia Alvarez, L., Demuth, D., Muthutantri, A., Skovgaard, R., Evans, M. · 2015 · International Journal of Clinical Practice
  51. History of glucagon-like peptide-1 receptor agonists
    Radwan Darwish, Ghena Abu-Sharia, Alexandra E. Butler · 2025 · Pharmacological Research
  52. Efficacy and tolerability of taspoglutide versus pioglitazone in subjects with type 2 diabetes uncontrolled with sulphonylurea or sulphonylurea‐metformin therapy: a randomized, double‐blind study (T‐emerge 6)
    Richard E. Pratley, Dragan Urosevic, Mark N. Boldrin, R. Balena, for the T‐emerge 6 Study Group · 2012 · Diabetes Obesity and Metabolism
  53. Evaluating the Long-Term Cost-Effectiveness of Daily Administered GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes in the United Kingdom
    Barnaby Hunt, Qing Ye, William J. Valentine, Donna Ashley · 2017 · Diabetes Therapy
  54. Effect of Long-term Incretin-Based Therapies on Ischemic Heart Diseases in Patients with Type 2 Diabetes Mellitus: A Network Meta-analysis
    Che‐Yi Chou, Ying‐Tzu Chang, Jia-Lian Yang, Jiun‐Yi Wang, Tsui-Er Lee, Ruey‐Yun Wang, Chin‐Chuan Hung · 2017 · Scientific Reports
  55. Cost-Effectiveness of Newer Antidiabetic Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review
    Jiejin Zhu, Ying Zhou, Qingyu Li, Gang Wang · 2023 · Advances in Therapy
  56. Recent achievements and future directions of anti-obesity medications
    Gerald Grandl, Aaron Novikoff, Xue Liu, Timo D. Müller · 2024 · The Lancet Regional Health - Europe
  57. Cost Effectiveness of Liraglutide in Type II Diabetes: A Systematic Review
    Patrick Zueger, Neil M. Schultz, Todd A. Lee · 2014 · PharmacoEconomics
  58. Advances in Medical Therapy for Weight Loss and the Weight-Centric Management of Type 2 Diabetes Mellitus
    Leon I. Igel, Amanda G. Powell, Caroline Margaret Apovian, Louis J. Aronne · 2011 · Current Atherosclerosis Reports
  59. Evaluating the Long-Term Cost-Effectiveness of Liraglutide Versus Exenatide BID in Patients With Type 2 Diabetes Who Fail to Improve With Oral Antidiabetic Agents
    William J. Valentine, Andrew John Palmer, Morten Lammert, J Langer, Michael Brändle · 2011 · Clinical Therapeutics
  60. The Intersection of Safety and Adherence: New Incretin‐Based Therapies in Patients with Type 2 Diabetes Mellitus
    Barbara J.M. Zarowitz, Christopher Conner · 2009 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
  61. Longitudinal Modeling of the Relationship Between Mean Plasma Glucose and HbA1c Following Antidiabetic Treatments
    J.B. Møller, Rune Viig Overgaard, MC Kjellsson, Niels Rode Kristensen, Søren Klim, SH Ingwersen, MO Karlsson · 2013 · CPT Pharmacometrics & Systems Pharmacology
  62. Liraglutide Versus SGLT-2 Inhibitors in People with Type 2 Diabetes: A Network Meta-Analysis
    Maria F. Lorenzi, Uffe Jon Ploug, J Langer, Rasmus Skovgaard, Michael J. Zoratti, Jeroen Paul Jansen · 2016 · Diabetes Therapy
  63. Liraglutide effects on beta‐cell, insulin sensitivity and glucose effectiveness in patients with stable coronary artery disease and newly diagnosed type 2 diabetes
    Christian Anholm, Preman Kumarathurai, Lene Rørholm Pedersen, Olav Wendelboe Nielsen, Ole Peter Kristiansen, Mogens Fenger, Sten Madsbad, Ahmad Sajadieh, Steen B. Haugaard · 2017 · Diabetes Obesity and Metabolism
  64. The effects of GLP-1 analogues on pre-diabetes of the children
    Qingxia Zhou, Zi-Yu Wang, Hua-Feng Zhao, Shan Wang · 2017 · Experimental and Therapeutic Medicine
  65. Pharmacokinetic and Chemical Synthesis Optimization of a Potent d -Peptide HIV Entry Inhibitor Suitable for Extended-Release Delivery
    Joseph S. Redman, J. Nicholas Francis, Robert Marquardt, Damon I. Papac, Alan L. Mueller, Debra M. Eckert, Brett D. Welch, Michael S. Kay · 2018 · Molecular Pharmaceutics
  66. Incretin-based medications (GLP-1 receptor agonists, DPP-4 inhibitors) as a means to avoid hypoglycaemic episodes
    Johan Farngren, Bo Åhrén · 2019 · Metabolism
  67. New Drugs in Development for the Treatment of Diabetes
    Terri L. Levien, Danial E. Baker · 2009 · Diabetes Spectrum
  68. Weight Management in Overweight and Obese Patients with Type 2 Diabetes Mellitus
    Ioannis Kyrou, Sudhesh Kumar · 2010 · The British Journal of Diabetes
  69. Untitled work
    Petrie · 2016 · 10.1097/hjh.0000000000000890
  70. Anagliptin increases insulin-induced skeletal muscle glucose uptake via an NO-dependent mechanism in mice
    Sato, Hiroyuki, Kubota, Naoto, Kubota, Tetsuya, Takamoto, Iseki, Iwayama, Kaito, Tokuyama, Kumpei, Moroi, Masao, Sugi, Kaoru, Nakaya, Keizo, Goto, Moritaka et al. · 2016 · Diabetologia
  71. Potential contributors to variation in weight‐loss response to liraglutide
    Webster, Chelsi M., Mittal, Neha, Dhurandhar, Emily J., Dhurandhar, Nikhil V. · 2023 · Obesity Reviews
  72. Oral Small-Molecule GLP-1 Receptor Agonists: Mechanistic Insights and Emerging Therapeutic Strategies
    Héctor Iván Saldívar-Cerón, Jorge Arturo Vargas-Camacho, Sonia León‐Cabrera, Paola Briseño-Díaz, Ari Evelyn Castañeda-Ramírez, Axel Eduardo Muciño-Galicia, María Regina Díaz-Domínguez · 2025 · Scientia Pharmaceutica
  73. Long-lasting anti-diabetic efficacy of PEGylated FGF-21 and liraglutide in treatment of type 2 diabetic mice
    Xianlong Ye, Jianying Qi, Guiping Ren, Pengfei Xu, Yunzhou Wu, Shenglong Zhu, Dan Yu, Shujie Li, Qiang Wu, Rasool Lubna Muhi et al. · 2015 · Endocrine
  74. The Gut as an Endocrine Organ: Role in the Regulation of Food Intake and Body Weight
    Audrey Melvin, Carel Wynand le Roux, Neil Gerard Docherty · 2016 · Current Atherosclerosis Reports
  75. Hypoglycemic drug liraglutide alleviates low muscle mass by inhibiting the expression of MuRF1 and MAFbx in diabetic muscle atrophy
    Dongmei Fan, Yue Wang, Bowei Liu, Fuzai Yin · 2022 · Journal of the Chinese Medical Association
  76. Utilization of glucagon-like peptide-1 receptor agonists in children and adolescents in China: a real-world study
    Yilong Yan, Ying Gong, Meizhu Jiang, Yiming Gao, Shanshan Guo, Jiping Huo, Zhigang Zhao, Cao Li · 2023 · Frontiers in Endocrinology
  77. Diabetes: glycaemic control in type 2 (drug treatments).
    Kees J. Gorter, Floris A Van de Laar, P. G. H. Janssen, Sebastiaan T. Houweling, Guy E.H.M. Rutten · 2012 · Europe PMC (PubMed Central)
  78. Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States
    Won Chan Lee, Christopher Conner, Mette Hammer · 2010 · Clinical Therapeutics
  79. Vesiculopustular dermatosis: An uncommon side-effect of liraglutide?
    Femke Besemer, Arie J. Verschoor, Michaëla Diamant, Roel P.L.M. Hoogma · 2012 · Journal of Diabetes and its Complications
  80. Is the GLP-1 system a viable therapeutic target for weight reduction?
    Jenny Tong, Darleen A. Sandoval · 2011 · Reviews in Endocrine and Metabolic Disorders
  81. Liraglutide in oral antidiabetic drug combination therapy
    Alan J. Garber · 2012 · Diabetes Obesity and Metabolism
  82. Liraglutide in Adults with Type 2 Diabetes: Global Perspective on Safety, Efficacy and Patient Preference
    Daisuke Yabe, Yutaka Seino · 2011 · Clinical Medicine Insights Endocrinology and Diabetes
  83. How Consistent is the Relationship between Improved Glucose Control and Modelled Health Outcomes for People with Type 2 Diabetes Mellitus? a Systematic Review
    Xinyang Hua, Thomas Wai-Chun Lung, Andrew John Palmer, Lei Si, William H. Herman, Philip Clarke · 2016 · PharmacoEconomics
  84. Tombul hazelnut (Corylus avellana L.) peptides with DPP-IV inhibitory activity: In vitro and in silico studies
    Ahmet Furkan Çağlar, Ayşe Gülden Göksu, Bilal Çakır, İbrahim Gülseren · 2021 · Food Chemistry X
  85. Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin
    Kjeld Hermansen, Ronette L. Kolotkin, Mette Hammer, Milan Zdravkovic, David Richard Matthews · 2010 · Primary care diabetes
  86. Focus on Incretin-Based Therapies: Targeting the Core Defects of Type 2 Diabetes
    Paul S. Jellinger · 2011 · Postgraduate Medicine
  87. Incretin-Based Therapies in Complex Patients: Practical Implications and Opportunities for Maximizing Clinical Outcomes: A Discussion with Dr. Vivian A. Fonseca
    Vivian Andrew Fonseca · 2010 · The American Journal of Medicine
  88. The role of incretin-based therapies in prediabetes: A review
    Hala Ahmadieh, Sami T. Azar · 2014 · Primary care diabetes
  89. Glimepiride use is associated with reduced cardiovascular mortality in patients with type 2 diabetes and chronic heart failure: a prospective cohort study
    Wu He, Gang Yuan, Yu Han, Yongcui Yan, Gen Li, Chengcheng Zhao, Jingshan Shen, Xiangrui Jiang, Chen Chen, Li Ni et al. · 2022 · European Journal of Preventive Cardiology
  90. Laparoscopic adjustable gastric banding with liraglutide in adults with obesity and type 2 diabetes (GLIDE): a pilot randomised placebo controlled trial
    Cláudia Matta-Coelho, Laurence J. Dobbie, James Crane, Abdel Douiri, Annastazia Learoyd, Olanike Okolo, Spyros Panagiotopoulos, Dimitri J. Pournaras, Sasindran Ramar, Francesco Rubino et al. · 2023 · International Journal of Obesity
  91. Add-on therapies to metformin for type 2 diabetes
    Mansur E. Shomali · 2010 · Expert Opinion on Pharmacotherapy
  92. Efficacy of Liraglutide in a Real-Life Cohort
    Anthony David Heymann, ‪Yasmin Maor‬‏, Inbal Goldstein, Lora Todorova, Perlit Schertz-Sternberg, Avraham Karasik · 2014 · Diabetes Therapy
  93. Harnessing the incretin system beyond glucose control: Potential cardiovascular benefits of GLP-1 receptor agonists in type 2 diabetes
    Bertrand Cariou · 2012 · Diabetes & Metabolism
  94. Alternative dosing strategies for liraglutide in patients with type 2 diabetes mellitus
    Adriane B. Marino, Sabrina W. Cole, Donald S. Nuzum · 2014 · American Journal of Health-System Pharmacy
  95. Clinical Studies of Liraglutide, a Novel, Once‐Daily Human Glucagon‐Like Peptide‐1 Analog for Improved Management of Type 2 Diabetes Mellitus
    Scott R. Drab · 2009 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
  96. The efficacy and safety of liraglutide
    Kyeong-Hye Jeong, Bong Kyu Yoo · 2011 · International Journal of Clinical Pharmacy
  97. Understanding GLP-1 Analogs and Enhancing Patient Success
    Davida F. Kruger, Bruce W. Bode, Geralyn R. Spollett · 2010 · The Science of Diabetes Self-Management and Care
  98. Liraglutide
    Jennifer Nicole Clements, Kayce M. Shealy · 2015 · Annals of Pharmacotherapy
  99. IDegLira: Redefining insulin optimisation using a single injection in patients with type 2 diabetes
    Eugene Hughes · 2016 · Primary care diabetes
  100. Clinical factors associated with the occurrence of nausea and vomiting in type 2 diabetes patients treated with glucagon‐like peptide‐1 receptor agonists
    Megumi Shiomi, Tesshu Takada, Yoïchi Tanaka, Keiko Yajima, Akira Isomoto, Masaki Sakamoto, Katsuya Otori · 2018 · Journal of Diabetes Investigation